Introduction to Novel Pharmaceutical

Substantial clinical and research efforts are being invested to develop novel pharmaceutical agents.

The results demonstrate that certain medicinal plants have a high antiviral potential and may serve as a lead to develop novel pharmaceutical agents to cure PED as well as the diseases caused by other coronaviruses.

Background Developing novel pharmaceuticals demands substantial investment despite high uncertainty of success and ultimate market value.

Pharmacological reviews on medicinal plants will provide valuable information; thus, Cassia fistula L can provide important discoveries of valuable bioactive natural products facilitating in developing novel pharmaceuticals products.

Advanced in vitro models, which closely mimic critical aspects of the pathology, have emerged as valuable platforms to investigate novel pharmaceutical therapies for the treatment of SSc.

Current research in the field of ischemic stroke focuses on better understanding the pathophysiology of stroke, to develop and investigate novel pharmaceutical targets.

In 2020, one novel pharmaceutical agent for small animals, the ACTH analog tetracosactide for the assessment of adrenocortical function in dogs, were released on the German market.

In 2020, one novel pharmaceutical agent for horses or food-producing animals was released on the German market, rendering the inhaled glucocorticoid ciclesonide (Aservo EquiHaler®) available for horses for the first time.

The new form of cholecalciferol would be better designing novel pharmaceutical formulations that might be more stable and more efficacious for the prevention and treatment of various diseases such as vitamin D deficiency, rickets, osteoporosis, arthritis, multiple sclerosis, cancer, diabetes mellitus, mental disorders, cardiovascular diseases, hypertension, infections, influenza, cognitive impairment in older adults, Parkinson’s and Alzheimer’s diseases, autoimmune disease, dementia, glucose intolerance, multiple sclerosis, etc.

Insights gained from the application of polyphasic linkage concepts should be useful for designing novel pharmaceutical ligands to regulate condensates.

In 2020, one novel pharmaceutical agent for small animals, the ACTH analog tetracosactide for the assessment of adrenocortical function in dogs, were released on the German market.

This includes several newly developed methods for preparation of the implant including endotoxin removal, appropriate sterilization of raw materials, formulation of novel pharmaceutical agents, and loading of agents into drug delivery reservoirs.

In the recent years, progress in nanotechnology has significantly contributed to the development of novel pharmaceutical formulations to overcome the drawbacks of conventional treatments and improve the therapeutic outcome in many diseases, especially cancer.

The new form of cholecalciferol would be better designing novel pharmaceutical formulations that might be more stable and more efficacious for the prevention and treatment of various diseases such as vitamin D deficiency, rickets, osteoporosis, arthritis, multiple sclerosis, cancer, diabetes mellitus, mental disorders, cardiovascular diseases, hypertension, infections, influenza, cognitive impairment in older adults, Parkinson’s and Alzheimer’s diseases, autoimmune disease, dementia, glucose intolerance, multiple sclerosis, etc.

Although terrestrial medicinal plants have been the focus for the development of NPs, however, in the last three decades, marine origins that include invertebrates, plants, algae, and bacteria have unearthed numerous novel pharmaceutical compounds, generally referred as marine NPs and are evolving continuously as discipline in the molecular targeted drug discovery with the inclusion of advanced screening tools which revolutionized and became the component of antitumor modern research.

He had worked for a pharmaceutical company for over 10 years, creating novel pharmaceutical compounds.

This study lays the grounds for further investigations insight novel pharmaceutical strategies targeting key effectors involved in the molecular cascade triggered by HA.

J Biochem 2017;161:99-111) showed a specific glycosylation at a site proximal to the β-secretase cleavage site and decreased productions of Aβ1-40 and Aβ1-42 in HEK293T cells transfected with a particular mucin-type glycan initiation enzyme, GalNAc-T6, indicating a novel pharmaceutical strategy to inhibit the production of Aβ through the upregulation of mucin-type O-glycosylation.

An option to avoid toxicity is represented by the targeted cancer treatment using novel pharmaceutical dosage forms.

Overall, the obtained data confirmed that the inclusion complexes prepared by kneading followed by spray-drying, especially those based on HP-β-CD, appeared to be the most promising formulations and, therefore, could be encouragingly explored in the development of novel pharmaceutical dosage forms containing DRO, presumably with reduced side effects and improved safety profile.

According to the physicochemical properties, especially high swelling ability and high viscosity nature, dried DIMs showed the possibility to be a novel pharmaceutical excipient.

Moreover, the data intelligence modeling demonstrates the reliability and satisfactory of ANFIS as a hybrid model over the other two models with increased performance skills in modeling the compaction properties of these novel pharmaceutical excipients.

Characterisation of microRNAs that produce an effect on neurological activity, such as miR-324, and identification of the pathways they regulate will allow a better understanding of the processes involved in normal neurological function and in turn may present novel pharmaceutical targets in treating neurological disease.

Conclusion This study further supports OTRs as a novel pharmaceutical target for drug delivery.

Use of plants among the two tribes reflects their interest in ethno-medicine and further investigation on under-explored species may lead to the discovery of novel pharmaceutical products.

Chalcones and flavonoids constitute a large family of plant secondary metabolites that have been explored as a potential source of novel pharmaceutical products.

(+)-Albaconol, (+)-neoalbaconol and two yahazunol isomers (24 and 25) were witnessed to be the novel pharmaceutical leads.

(+)-Albaconol, (+)-neoalbaconol, and two (+)-yahazunol isomers (24 and 25) proved to be the novel pharmaceutical leads.

Poly-Ethylene-Glycol (PEG) attachment is a novel pharmaceutical technology to improve the efficacy and safety of chemotherapies.

The major concern is about the possible occurrence of adverse effects, particularly in the context of the use of novel pharmaceutical technologies such as mRNA.

Special consideration is given to inhibitors of these enzymes and their role as potential new antifungals and emerging tools for the discovery of novel pharmaceutical drugs and antibiotics in fungal producer strains.

The discovery of novel materials and functional molecules can help to solve some of society's most urgent challenges, ranging from efficient energy harvesting and storage to uncovering novel pharmaceutical drug candidates.

Advanced in vitro models, which closely mimic critical aspects of the pathology, have emerged as valuable platforms to investigate novel pharmaceutical therapies for the treatment of SSc.

The discovery and development of novel pharmaceutical therapies is rapidly transitioning from a small molecule–dominated focus to a more balanced portfolio consisting of small molecules, monoclonal antibodies, engineered proteins (modified endogenous proteins, bispecific antibodies, and fusion proteins), oligonucleotides, and gene-based therapies.

In sum, our novel zebrafish model of liver steatosis and steatohepatitis is a promising model in which to study the intricate associations between NAFLD and T2D, and may serve as an amenable platform for screening novel pharmaceutical interventions.

There is a pressing need for novel pharmaceutical interventions for the major neuropsychiatric diseases schizophrenia (SCZ), bipolar disorder (BPD), major depressive disorder (MDD), and autism spectrum disorder (ASD).

This review offers an in-depth insight into its novel Pharmaceutical applications as well as sources, processing, physicochemical properties, and nutritional and physiological activities.

Microbes have been explored as a potential source of bioactive compounds for novel pharmaceutical applications.

The obtained results demonstrate the high potential of flavonoids Qu and Rut to the development of novel pharmaceutical forms using the example of Camphecene in the form of molecular complexes, as the novel forms of delivery.

In future, the inclusion of allantoin-rich extracts in various novel pharmaceutical forms for new therapeutic applications could be achieved.

All results of this paper clearly reveal the feasibility and capability of SSE 3D printing technology as a novel pharmaceutical manufacturing technique to fabricate personalized medicines and modulate drug dissolution profiles.

All the results demonstrated the potential and capability of semi-solid extrusion 3-dimensional printing as a novel pharmaceutical manufacturing technique to provide a dynamic and highly accurate controllable system for preparing patient-tailored medicines.

BK channels may also offer other potentially broad and underrecognized promising targets for novel pharmaceutical development.

Proteomic analyses of intervertebral discs (IVDs) reveal information for understanding the fundamentals of biological processes and pathogenesis but also provide insights for novel pharmaceutical development.